Bristol-Myers Squibb (BMY) Reports Eight-Year Data for Opdiv

Bristol-Myers Squibb (BMY) Reports Eight-Year Data for Opdivo Plus Yervoy Continued to Demonstrate Longest Survival Benefit vs. Sunitinib

Bristol-Myers Squibb (BMY) Reports Eight-Year Data for Opdivo Plus Yervoy Continued to Demonstrate Longest Survival Benefit vs. Sunitinib

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , American , Nizar Tannir , Bristol Myers Squibb , Dana Walker , Department Of Genitourinary Medical Oncology , Database Consortium , Division Of Cancer Medicine , American Society Of Clinical Oncology , International Metastatic , University Of Texas , Md Anderson Cancer Center , American Society , Clinical Oncology , Cancers Symposium , Hazard Ratio , Confidence Interval , Genitourinary Medical Oncology , Cancer Medicine , Bristol Myers , Myers Squibb ,